Molecular Devices Launches SoftMax Pro 7.6 GLP Mode for Lab Compliance
News related to:Molecular Devices · 1 min read
Molecular Devices, a leading provider of life science solutions, has introduced SoftMax® Pro 7.6 GLP Mode, the latest addition to its SoftMax Pro 7.6 GxP Software Suite. This new software mode is designed to support laboratories at various stages of compliance maturity, helping teams strengthen data integrity, traceability, and workflow oversight.
The new GLP Mode is particularly beneficial for development-stage laboratories that may not require the extensive infrastructure associated with Good Manufacturing Practice (GMP) operations but still need practical governance and oversight tools. According to Mary Duseau, President of Molecular Devices, the software suite helps bridge the gap between discovery and regulated environments, ensuring that laboratories can maintain consistent workflow execution and audit-ready reporting.
The new GLP Mode includes enhanced user management, electronic signatures, audit-ready reporting, and controls that help standardize data management across teams. It is compatible with the full line of SoftMax Pro SpectraMax® microplate readers and is now available worldwide. The expanded suite helps laboratories apply the right level of control as their work progresses from development and non-clinical research toward more regulated environments, ensuring that data remains defensible and accountable.
The SoftMax Pro 7.6 GxP Software Suite is designed to support biotechnology, pharmaceutical, contract research, and translational research organizations. It provides practical ways to increase oversight of plate reader data and support evolving compliance expectations. The software suite is part of Molecular Devices' broader commitment to accelerating the discovery and development of new therapeutics through high-performance bioanalytical measurement systems, software, and consumables.
With the addition of GLP Mode, the company aims to help laboratories advance confidently from discovery toward regulated compliance, ensuring that data integrity and accountability are maintained throughout the research process.